{"schema_version":"secwatch.filing_event.v1","accession":"0001778922-26-000018","form_type":"8-K","ticker":"SGP","cik":"0001778922","company_name":"SpyGlass Pharma, Inc.","filed_at":"2026-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.147332+00:00","generated_at":"2026-05-15T08:52:04.212686+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"SpyGlass Pharma reports FY2025 net loss $39.9M; positive Phase 1/2 data and $172.5M IPO","bullets":["Net loss of $12.6M in Q4 2025 ($5.72/sh) and $39.9M for FY2025 ($17.98/sh).","Cash $107.4M at Dec 2025; plus $172.5M IPO gross proceeds; runway through 2028.","Positive 12-month Phase 1/2 data: 97% of patients off IOP-lowering drops; mean IOP reduction 34-42%.","Phase 3 trials (SGP-005/SGP-006) enrolling; full enrollment expected 2027; BIM-DRS FIH trial in H2 2026.","Appointed Jean-Frédéric Viret as CFO and Habib Dable to board."],"urls":{"canonical":"https://secwatch.observer/filing/0001778922-26-000018","json":"https://secwatch.observer/filing/0001778922-26-000018.json","markdown":"https://secwatch.observer/filing/0001778922-26-000018.md","text":"https://secwatch.observer/filing/0001778922-26-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1778922/000177892226000018/0001778922-26-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1778922/000177892226000018/sgp-20260326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:52:04.212686+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"469b4c7b4b5e23b0a8a3eb39402b99635d0640e2","claim":"SpyGlass Pharma, Inc. reported financial results for fourth quarter and fiscal year ended December 31, 2025.","evidence_excerpt":"On March 26, 2026, SpyGlass Pharma, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1778922/000177892226000018/0001778922-26-000018-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and fiscal year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}